Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Short term Debt (2016 - 2026)

Usana Health Sciences has reported Short term Debt over the past 7 years, most recently at $14.0 million for Q2 2026.

  • Quarterly Short term Debt fell 39.13% to $14.0 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Apr 2026, down 39.13% year-over-year, with the annual reading at $14.0 million for FY2026, 39.13% down from the prior year.
  • Short term Debt was $14.0 million for Q2 2026 at Usana Health Sciences, roughly flat from $14.0 million in the prior quarter.
  • Over five years, Short term Debt peaked at $23.0 million in Q4 2024 and troughed at $786000.0 in Q4 2023.
  • The 5-year median for Short term Debt is $14.0 million (2026), against an average of $12.3 million.
  • Year-over-year, Short term Debt skyrocketed 2826.21% in 2024 and then tumbled 39.13% in 2026.
  • A 5-year view of Short term Debt shows it stood at $10.0 million in 2022, then plummeted by 92.14% to $786000.0 in 2023, then surged by 2826.21% to $23.0 million in 2024, then changed by 0.0% to $23.0 million in 2025, then crashed by 39.13% to $14.0 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Short term Debt are $14.0 million (Q2 2026), $14.0 million (Q1 2026), and $23.0 million (Q1 2025).